This collaborative effort between Chinese and Japanese scientists has advanced the technology, demonstrating China's strategic capabilities in biomedical materials through multiple patent filings and international development.

This breakthrough fills an international knowledge gap regarding collagen fiber self-assembly, underpinning developments in tissue regeneration, aesthetic medicine, anti-aging, and wound repair, supported by four Chinese invention patents.

The structural insights gained provide a scientific basis for the industrialization and clinical application of biomimetic collagen, addressing key challenges in the field.

Market forecasts project China's biomimetic collagen sector will grow rapidly from under one million yuan in 2025 to over 6.7 billion yuan by 2030, with a CAGR exceeding 150%, and POGMENT collagen has been incorporated into national standards.

LivingPhoenix has filed multiple patents for POGMENT, including four in China and several international applications, emphasizing its innovation and commercial potential, with efforts underway for high-end medical and aesthetic markets.

The company has achieved mass production of POGMENT collagen, with an annual capacity of 30 tons, aiming to significantly reduce costs and position it as a competitive alternative to recombinant collagen.

LivingPhoenix's POGMENT collagen has been peer-reviewed and published in the prestigious Q1 SCI journal 'Frontiers in Bioengineering and Biotechnology,' affirming its scientific credibility and supporting its applications in medical and cosmetic fields.

The company has established a comprehensive classification system for POGMENT collagen, facilitating its use across medical aesthetics, tissue engineering, and high-end biomedical materials, with ongoing registration and approval processes.

Recognized for its scientific validation, POGMENT collagen has been filed with China's NMPA and incorporated into official standards, highlighting its potential for clinical and industrial applications.

LivingPhoenix holds multiple intellectual property rights, including three material patents and one use patent granted, with additional patents filed internationally, and has registered in key markets such as the U.S., EU, UK, South Korea, and Japan.

The innovative collagen technology originated from Kyoto University, was introduced to China by Japanese scientists, and has been locally upgraded in Chengdu, resulting in a second-generation independent IP system developed by a global team of PhDs.

A major breakthrough was achieved through collaboration with Tianfu Jincheng Laboratory, utilizing advanced Cryo-EM technology to visualize collagen fiber bundles at high resolution, providing critical structural insights into collagen self-assembly.